55784-09-3

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 107-82-4 i-pentyl bromide 

Downstream Products

• 845786-06-3 tert-butyl [4-(isopentyloxy)phenyl]acetate 
• 1117803-04-9 1-(2,4-dihydroxyphenyl)-2-[4-(3-methylbutoxy)phenyl]ethanone 
• 1269194-82-2 C₃₂H₄₂O₅ 
• 1269194-81-1 C₃₀H₃₈O₅ 
• 1269194-80-0 C₂₈H₃₄O₅ 
• 1269194-79-7 C₂₆H₃₀O₅ 
• 1269194-78-6 C₂₄H₂₆O₅ 
• 1269194-85-5 C₃₈H₅₄O₅ 
• 1269194-84-4 C₃₆H₅₀O₅ 
• 1269194-83-3 C₃₄H₄₆O₅ 

Relevant academic research and scientific papers

Nematogenic and smectogenic liquid crystals from new heterocyclic isoflavone derivatives: Synthesis, characterization and X-ray diffraction studies

A new series of liquid crystals comprising eight heterocyclic isoflavone esters, 7-alkanoyloxy-3-[4′-(3-methylbutyloxyphenyl)]-4H-1-benzopyran-4- ones exhibiting enantiotropic nematic (N) and smectic C (SmC) phases were synthesized and investigated. The m

Synthesis and phase behavior of new isoflavone derivatives: Crystal structure of 7-hexyloxy-3-[4′-(3-methylbutyloxy)phenyl]-4H-1-benzopyran-4- one

This article describes the synthesis and mesomorophic behavior of a novel homologous series of 7-alkyloxy-3-[4'-(3-methylbutyloxyphenyl)-4H-1-benzopyran- 4-one. The title compounds were made up of central isoflavone core with branched and linear alkyloxy terminal chains at C-4' and C-7, respectively. The influences of linear alkyloxy terminal chain in different length of OR (where R=CnH2n+1; even number of n ranging from 4 to 18) were discussed. The thermal behavior especially the phase transition and respective enthalpy values of the compounds thus synthesized were analyzed using differential scanning calorimetry. The occurrence of mesophases under the polarized light has suggested the molecular orientation and arrangement of the title compounds. The molecular structure of compound 7-hexyloxy-3-[4'-(3methylbutyloxyphenyl)]-4H-1- benzopyran-4-one in crystal phase was confirmed by single-crystal X-ray diffraction of which the space group is P-1(#2) with the lattice parameters a=6.100(5) , b=11.704(10) , c=17.082(17) , =80.85(4), =85.56(4), =72.48(3), and V=1147.6(18) 3. The elongated alkyloxy terminal chains were found to be fully stretched in solid phase. All present compounds except the derivative with R=C4H9 were smectogenic.

MATRIX METALLOPROTEINASE INHIBITORS

Compounds of Formula (I), wherein R1 represents optionally substituted -C4-12 alkyl, -C2-10alkylcycloalkyl, -C2-6 alkyl heterocycloalkyl, -C2-6alkylaryl, optionally substituted 5- or 6- membered aryl or heteroaryl, except pyridinyl. Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6- membered aryl or heteroaryl ring; X represents COR3; R2 represents CONH2, CO2H, CO2R7, SO2R7 or SO2NR8R9, except that R2; may not represent CO2R7 when X is CONH2 ; R3 represents OR6, or NR8R9; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 represents H or C1-6 alkyl; R7 represents C1-6 alkyl; R8 and R9 each independently represents H or C1-6 alkyl or R8 and R9 together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; and physiologically functional derivatives thereof with the exception of [3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid and 3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid diethyl ether; butanedioic acid [3-methoxy-4-(phenylmethoxy)phenyl]; butanedioic acid [4-(phenylmethoxy)phenyl]; with the proviso that when R1 represents C4-12 alkyl, Z is other than a bond, O or CH2; and physiologically functional derivatives thereof , processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs) are described.